CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 501–600 of 661
Targeting ACAT1 for Precision Chemo‐Immunoprevention in Lung Cancer
Huang, M., Pan, J., Sei, S., Wang, Y., & You, M. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400430 · Cited by 2
Li, Z., Tian, M. L., Yang, Y., Wang, Y., Zhang, L., Huang, F., Xiao, W., Yin, X., Lin, X., & Tian, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600863 · Cited by 3
Development of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Mumba, C. N., Mwale, N. K., Mapulanga, V., & Ngalamika, O. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107099 · Cited by 2
Wu, Y., Xie, Y., Lin, J., Cui, J., Yang, H., Alenzi, M., Huang, P., Huang, A., & Huang, M. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17977-4 · Cited by 2
Lin, C.-I., Chiu, Y.-W., Yen, M.-S., Wang, Y., Wu, Y.-Y., & Chuang, Y.-H. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012460 · Cited by 2
Tang, Y., Hou, C., Cao, R., Song, Y., Shen, H. R., Zeng, S., Zhu, J. X., & Han, Y. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.06.003 · Cited by 2
CD103+ T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer
Mori, T., Tanaka, H., Deguchi, S., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., Lee, S., Muguruma, K., & Ohira, M. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10121 · Cited by 3
Liu, Y., Han, D., Ma, Q., Zheng, Y., Lin, Y., Yang, C., & Yang, L. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.12935 · Cited by 3
“Moreover, TICs can be effectively targeted using drugs (19,22).”
Tissue-Resident Memory T Cells Are Implicated in the Pathogenesis of Hypersensitivity Pneumonitis
Sendama, W., Funston, W., Rostron, A., & Simpson, A. J. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202212-2310le · Cited by 2
Fan, X., Nijman, H. W., de Bruyn, M., & Elsinga, P. H. (2024) · EJNMMI Research · doi:10.1186/s13550-023-01062-6 · Cited by 2
Du, X., He, Y., Dong, P., Yan, C., Wei, Y., Yao, H., & Sun, J. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-191 · Cited by 2
Ding, X., Chen, D., Zhang, Z., Qi, Y., Chen, D., Wen, J., Wang, Y., Cheng, H., Ji, C., Chen, L., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251350188 · Cited by 2
Habib, J. G., Liu, D., Crepeau, R. M., Wagener, M. E., & Ford, M. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081163 · Cited by 3
Williams, J. B., Pant, S. M., Kley, A. L., Rajmalani, B. A., Yapp, C., Zhang, J., Deans, K., Rotrosen, E. T., Sales, A., Sorger, P. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683143 · Cited by 2
“Their presence within tumors has been associated with improved prognosis and favorable responses to checkpoint blockade in multiple cancer types, including melanoma 16,21–25 .”
Phenotypic Differences of CD103+ Tissue-Resident Memory T Cells Associated with Various Cancers
Park, H. S., Jeon, Y., Lee, H., Lee, H. J., Kim, Y., Park, I. A., Bang, W. S., Lee, M., Cho, Y. J., Kim, J., et al. (2021) · Pathobiology · doi:10.1159/000518972 · Cited by 1
Wang, H., Huang, H., Lin, X., Chi, P., Chen, H., Chen, J., Mou, Y., Chen, Z., Yang, Q., & Guo, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010146 · Cited by 1
“Patients with higher intertumoral or circulating Tc cells generally have a slower progression and live longer (23).”
BackgroundT cell phenotype and clonality changes in myeloma patients with short overall survival
Behsen, A. D., Vandsemb, E. N., Slørdahl, T. S., Dybkær, K., Jakobsen, M. Z., Kashif, M., Lund, J., Luong, V., Olsnes, A. M., Waage, A., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.181096 · Cited by 2
Talayev, V. Y., Babaykina, O. N., Svetlova, M. V., Заиченко, И. Е., & Kurkova, E. V. (2025) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-trm-17842 · Cited by 1
Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes
O’Brien, L., Buckle, I., Rojas, I. L., Rosendahl, N., & Radford, K. J. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2521391 · Cited by 1
Huang, Z., Mandelkow, T., Raedler, J. B., Bady, E., Müller, J. H., Simon, R., Vettorazzi, E., Sauter, G., Ebner, J., & Blessin, N. C. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104248 · Cited by 1
Immediate variations in high‐dimensional circulating immune cells following pancreatectomy
Garnier, J., Palen, A., Durand, X., Ewald, J., Amara, A. B., Rouvière, M. S., Granjeaud, S., Bellan, G., Choisy, B., Verdonk, F., et al. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70059 · Cited by 1
Savage, G., Milne, K., Collinge, B. J., Yin, Y., Loos, P., Warren, M. E., Laumont, C. M., Keith, D., Nelson, B. H., Venturutti, L., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0445 · Cited by 1
Principe, N., Stevens, K. L. P., Phung, A., McCoy, M. J., Kidman, J., Ismail, A. G. M., Cook, A., Chopra, A., Watson, M., Robinson, B. W. S., et al. (2025) · Oxford Open Immunology · doi:10.1093/oxfimm/iqaf008 · Cited by 1
“The high levels of TGF β reported in the MPE could be driving the upregulation of CD103 and CD69, leading to the maintenance and retention of T RM in the MPE [20, 64].”
A lung specific escape of intravascular metastatic breast cancer cells from cytotoxic T cell killing
Kizner, M., Levi, N., Sochen, C., Ryvkin, J., Regev, O., Zarbock, A., Eisenbach, L., Biton, M., & Alon, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599751 · Cited by 1
Lindenstrøm, T., Panagiotopoulou, N., Cohen, S. B., Rodríguez, P. F., Woodworth, J. S., Morikawa, M., Halima, M., Maymann, C. M., Hu, T., Stull, S. M., et al. (2026) · Mucosal Immunology · doi:10.1016/j.mucimm.2026.02.001 · Cited by 1
Liang, B., & Zou, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-43719-x · Cited by 1
Lee, H. J., Jeong, B.-K., Gong, G., Lee, M., & LEE, H. J. (2026) · Cancer Research and Treatment · doi:10.4143/crt.2025.1416 · Cited by 1
“…cell recognition and elimination. e p The anti-tumor cytotoxicity of tumor-infiltrating CD8+ T RM cells is highly dependent on this CD103-E-cadherin interaction, as evidenced by the significant inhibition of target cell lysis when this interaction is blocked by neutralizing antibodies [8,19,22].”
Xie, D., Tian, Y., Zhang, J., He, M., & Lu, L. W. A. G. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014806 · Cited by 1
Tu, X., Zeng, X., 孙要良, Ouyang, Y., Zhu, L., Yin, P., Pavelko, K. D., Leon-Ferre, R., Jiang, Y., Dong, H., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci192285 · Cited by 2
Vaudiau, N., Bourdely, P., Semitekolou, M., Ok, A., Gorline, L., Coulibaly, A. S. K., Rastello, M., Semervil, A., Savoldelli, R., Gerber-Ferder, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77641-7 · Cited by 1
“…between CD8 + TILs with a T RM phenotype and favorable outcomes, and increased response rates to immune checkpoint inhibition in human lung cancer 1,3,5 – 7, 9 In cancer, CD8 + T cells are initially activated in tumor-draining lymph nodes (tdLN) and terminally differentiate within the tumor 22,23 .”
InfluentialImmunological microenvironment in the clinical outcome of some solid tumors
Manikhas, G. M., Кутукова, С. И., Beliak, N. P., Раскин, Г. А., Yaremenko, A. I., Ivaskova, Y. V., Ermakova, T. S., & Bozhor, S. S. (2016) · Russian Journal of Oncology · doi:10.18821/1028-9984-2015-21-1-55-59 · Cited by 1
Active Immunotherapy in cancer – Current Status
Khamar, B. M. (2018) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2018.01.000513 · Cited by 1
“Early evidence indicating importance of immune cells came from histopathological evaluation of tumor infiltrating immune cells and their role in prognosis [1-7].”
DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data
Gameiro, S. F., Ghasemi, F., Barrett, J. W., Koropatnick, J. D., Nichols, A. C., Mymryk, J. S., & Vareki, S. M. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.040 · Cited by 1
Immunology and Immunotherapy of Ovarian Cancer
Wilczyński, J. R., Nowak, M., & Wilczyński, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_20 · Cited by 1
On the Individualized Cancer Management
(2023) · Medical & Clinical Research · doi:10.33140/mcr.08.11.01 · Cited by 1
Applications of Multiplex Immunohistochemistry in Evaluating Spatiotemporal Heterogeneity of T Cells
Machuca-Ostos, M., de Martines, T., Yoshimura, K., Mitsuda, J., Saburi, S., Kimura, A., Morimoto, H., Yoshizawa, K., Sakurai, N., Murakami, N., et al. (2025) · Immuno · doi:10.3390/immuno5010007 · Cited by 2
Xu, Y., Luo, H., Wang, J., Liu, H., Chen, L., Ji, H., Deng, Z., & Liu, X. (2025) · Advanced Science · doi:10.1002/advs.202503557 · Cited by 3
Pleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases
Rustum, Y. M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-693-6 · Cited by 2
Sun, H., He, S., Meng, L., Wang, Y., Zhang, H., Liu, Y., Wang, J., Tao, M., Barta, S. K., Dulaimi, E., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3294754 · Cited by 1
Wang, H., Huang, H., Mou, Y., Chi, P., Lin, X., Chen, H., Chen, J., Chen, Z., Yang, Q., & Guo, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1447293/v1 · Cited by 1
Abe, T., Yamashita, K., Nagasaka, T., Fujita, M., Ueda, Y., Miyake, S., Ito, R., Adachi, Y., Ando, M., Tsuneki, T., et al. (2026) · medRxiv · doi:10.64898/2026.05.26.26353629 · Cited by 1
Nizard, M. (2015) · theses.fr (ABES) · doi:10.70675/3d3079abz13a3z421bzb96ezd30e886c45b1 · Cited by 1
Recirculating and Resident Memory CD8 + T Cells
Gebhardt, T., & Bedoui, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.08008-5
Leonard, F., & Godin, B. (2016) · Fundamental biomedical technologies · doi:10.1007/978-3-319-43525-1_4 · Cited by 1
Watza, D., Purrington, K. S., Chen, K., & Schwartz, A. G. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.35
“Likewise, two other recent studies have demonstrated a similar link between CD103+ CD8+ TRM cells and patient prognosis in lung cancer (8,9).”
ResultDetermining the best combination of TLR Agonist and Tumour Peptide for Cancer Vaccination
Gaskarth, D. (2017) · Otago University Research Archive (University of Otago)
Rôle des Pioneer Translation Products (PTPs) dans la réponse immunitaire anti-tumorale.
Pierson, A. (2017) · theses.fr (ABES) · doi:10.70675/5393772bz8a05z410dzb7b7z555ea60d5f4c
Bartkowiak, T. (2017) · Digital Commons-TMC (Texas Medical Center)
T cells in solid tumors : investigating the immunomodulation in the tumor microenvironment
Hartana, C. A. (2018) · Figshare
Bublevič, J. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.12.002325
Complexities of the Lung Tumor Microenvironment
Egelston, C. A., & Lee, P. P. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_9
Transcriptional control of tissue-resident memory T cell generation
Cvetkovski, F. (2019) · doi:10.7916/d8-n16c-b343 · Cited by 1
Effern, M. (2019) · bonndoc (University of Bonn)
Etude des voies de recrutement des cellules dendritiques dans une tumeur solide
Boulet, D. (2017) · theses.fr (ABES) · doi:10.70675/e4dd9c54zb11fz423ezaddfz0c7f6af1af14
The effect of local immunity on gastric cancer prognosis
Хакимова, Г. Г., Tryakin, A. A., Заботина, Т. Н., Borunova, A. A., Malikhova, O. A., Juraev, F. M., Николаевич, П. И., Захарова, Е. Н., & Tabakov, D. (2020) · Journal of Modern Oncology · doi:10.26442/18151434.2020.1.200049
Multi-layered epigenetic control of T cell fate decisions
Yu, B. (2018) · eScholarship (California Digital Library)
Immunochemical approaches to monitor and modulate the adaptive immune system
Luimstra, J. J. (2020) · Leiden Repository (Leiden University)
Calin, G., Hofman, P. M., & Mani, S. A. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-452-5
Cappuccini, F., Mueller, J., Pollock, E., Hill, A. V. S., Ternette, N., & Redchenko, I. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438563
“[65, 66] and they can protect against tumour challenge in mice [67].”
BackgroundMay, H. D. (2020) · UNM’s Digital Repository (University of New Mexico)
[Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].
Shu, C., Zhu, D., & Zhou, Q. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.04
Pasello, G., Felley‐Bosco, E., & Remon, J. (2022) · Frontiers research topics · doi:10.3389/978-2-88974-818-1
Faculty Opinions recommendation of Understanding subset diversity in T cell memory.
Pipkin, M. E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732725574.793562831
Pipkin, M. E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732992108.793562839
Belz, G. T. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736030378.793575846
Olive, D. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735695817.793574167
Tumor immunology and the application of immunotherapy in ovarian carcinoma
Paijens, S. T. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182133606
Tsokos, G. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732232814.793570401
Faculty Opinions recommendation of Tissue-Resident T Cells and Other Resident Leukocytes.
Pipkin, M. E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735023784.793562830
A Unique Epigenomic Landscape Defines CD8 + Tissue-Resident Memory T CellsPreprint
Buquicchio, F. A., Fonseca, R., Belk, J. A., Evrard, M., Obers, A., Qi, Y., Dániel, B., Yost, K. E., Satpathy, A. T., & Mackay, L. K. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4099073 · Cited by 2
Weeden, C. E., Gayevskiy, V., Marceaux, C., Batey, D., Tan, T., Yokote, K., Ribera, N. T., Clatch, A., Christo, S. N., Teh, C. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4187262
Gene and Cell Therapy: How to Build a BioDrug
Baumeister, S. H. C., & Woolfrey, A. E. (2022) · Pediatric oncology · doi:10.1007/978-3-031-06357-2_6
Zou, S., Ye, J., Zou, S., Tan, J., Wei, Y., & Xu, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2594514/v1
Efficacy of Individualized Cancer Management
Tsung, K., Xu, Z., & Hui, Z. (2023) · Journal of Cancer Research Reviews & Reports · doi:10.47363/jcrr/2023(5)181
Study of the immunopathogenesis of narcolepsy type-1 using original mouse models
Frieser, D. (2022) · theses.fr (ABES) · doi:10.70675/02b7c749z929fz4542za4c5z956b592bf2e1
Effet du microbiote intestinal sur la pharmaco-onco-immunologie des statines
Pukar, K. C. (2020) · theses.fr (ABES) · doi:10.70675/ff8b34e6z83e6z4a77z8a50z14b3a52080e9
Yang, G., Hu, M., Cai, S., Li, C., Yang, L., Zhao, M., Jing, H., Xing, L., & Sun, X. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00980-4
“…as the tumor-reactive cells in response to immunotherapy, with significant heterogeneity in functional status and spatial architecture [9, 14–19 , Whether the density of intratumoral CD8 + T cells increases in NSCLC after NAC has shown inconsistent results in several independent studies…”
Conventional T Cell Subsets and Their Roles Within the Tumor Microenvironment
Azimnasab-sorkhabi, P., Soltani-asl, M., Ansa-Addo, E. A., & Kfoury, J. R. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_332
Tissue‐resident memory T cells: Harnessing their properties against infection for cancer treatment
Fernandes, J., Veldhoen, M., & Ferreira, C. (2024) · BioEssays · doi:10.1002/bies.202400119 · Cited by 1
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Natural Killer Cells in the Human Lung
Marquardt, N., Ljunggren, H., & Michaëlsson, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_27-1
Yin, Z., Liu, Q., Maswikiti, E. P., & Chen, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5142794
Evaluation of Blood Cytotoxicity Against Tumor Cells Using a Live‐Cell Imaging Platform
Salvia, R., Rico, L. G., Morán, T., Olszowy, M. W., Ward, M. D., & Pétriz, J. (2025) · Cytometry Part A · doi:10.1002/cyto.a.24930
Vaudiau, N., Bourdely, P., Ok, A., Semitekolou, M., Gorline, L., Savoldelli, R., Gerber-Ferder, Y., Carmo, F. L. R. D., Semervil, A., Vétillard, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6455825/v1
Examining CD103 + Tissue‐Resident Memory T Cells in Nasopharyngeal Carcinoma
Thai, A. A., Young, R. J., Bressel, M., Brigitte, B.-N., Chua, M. L. K., Soni, P., Angel, C. M., Trigos, A., Rischin, D., & Solomon, B. (2025) · Head & Neck · doi:10.1002/hed.70026
“…association of CD103 + IC abundance and increased expression of immune checkpoint molecules in NPC is consistent with findings in other tumors and has been implicated in predicting response to immune checkpoint blockade, but its predictive role in NPC has not yet been examined [8, 11, 12, 28, 41].”
Rattanapitoon, S. K., Padchasuwan, N. H., La, N., & Rattanapitoon, N. K. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251385073
YuHan, A. I., Huang, M. J., MengYu, X. I. A. O., & Yuan, J. H. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0161
Sanders, C., Kittel, D. L., Heine, A., Strieth, S., Hattenhauer, T., Mispelbaum, R., Dietrich, D., Kristiansen, G., Brossart, P., & Toma, P. M. I. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101346
Yin, Z., Liu, Q., Maswikiti, E. P., Wang, Z., Bai, Y., Lin, X., Wang, Y., Ma, B., Gao, L., Shi, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1683916
Yang, G., Cai, S., Hu, M., Li, C., Yang, L., Zhang, W., Sun, J., Sun, F., Xing, L., & Sun, X. (2024) · Figshare · doi:10.6084/m9.figshare.26663506
Yang, G., Cai, S., Hu, M., Li, C., Yang, L., Zhang, W., Sun, J., Sun, F., Xing, L., & Sun, X. (2024) · Figshare · doi:10.6084/m9.figshare.26663509
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.